一次性配储液袋

Search documents
乐纯生物成功自研高通量过滤膜,以底层创新筑牢本土生物制药供应链安全防线
Huan Qiu Wang· 2025-05-06 09:37
Core Viewpoint - LePure Biotech has achieved a significant breakthrough with its self-developed Extreme™ PVDF sterilizing filter membrane, marking a major step for domestic bioprocess companies in ensuring supply chain security [1][2]. Downstream Demand Side - Historically, the Chinese biopharmaceutical upstream market has relied heavily on imported consumables, with over 95% market share held by multinational companies. However, domestic biopharmaceutical companies are now focusing on self-reliance to mitigate risks from international supply chain fluctuations [2]. - Currently, domestic single-use consumables and equipment account for over 50% of the biopharmaceutical R&D and production process, with LePure Biotech holding a competitive advantage in market share for filters and culture media [2]. - The Extreme™ PVDF filter membrane can process 2-3 times the amount of imported competitors per unit area during constant pressure filtration tests, significantly reducing production costs and improving efficiency [2]. Upstream Process Side - The introduction of the PVDF filter membrane is expected to fundamentally improve the quality of domestic virus removal filtration materials, which have faced high technical performance requirements [4]. - LePure Biotech has also successfully developed another widely used membrane material, the PES hydrophobic filter membrane, and plans to launch a complete range of PES ultrafiltration membrane products by the end of the year [4]. - The company emphasizes the importance of foundational R&D capabilities to stabilize supply chain security, having launched the Lekrius® membrane in 2021 and the Extreme™ PVDF filter membrane this year [4][6]. Product Development Strategy - LePure Biotech adopts a strategy of "strengthening foundational R&D, deepening application R&D, and optimizing overall processes" across three categories of consumables: single-use systems, cell culture, and filtration purification [6]. - The rapid growth of the filtration business has become the company's second growth curve, with plans to continue developing various product models to meet pharmaceutical market demands [6]. Market Position and Future Outlook - LePure Biotech recognizes both the advantages and challenges of "Chinese manufacturing capabilities," noting unique strengths in technology conversion efficiency, supply chain responsiveness, and cost-effectiveness [7]. - Despite the rapid development of domestic companies in formulation development and process stability, there remains a gap compared to established international brands, necessitating longer cycles for technology validation and market cultivation [7]. - The successful self-research by LePure Biotech provides a safer and more reliable supply chain assurance for the Chinese biopharmaceutical industry, positioning the company to play a more significant role in the global biopharmaceutical supply chain as more innovative products are launched [7].